comparemela.com
5
6
7
8
9
10
11
Latest Breaking News On - Asco annual meeting - Page 4 : comparemela.com
Advent of PARP Inhibitors in Metastatic CRPC
Moving on to discuss metastatic castration-resistant prostate cancer, panelists highlight the evolving role of PARP inhibition in this setting.
Treatment-approaches
Prostate-cancer
Metastatic-prostate-cancer
Nmcrpc
Castration-resistant-prostate-cancer
Parp-inhibitors
Parp-inhibition
Tissue-biopsy
Liquid-biopsy
Somatic-testing
Germline-testing
Bispecifics in Multiple Myeloma: Adverse Event Management
Expert perspectives on adverse event management in patients on bispecific therapy for multiply relapsed multiple myeloma.
Evolving-treatment-paradigm
Multiple-myeloma
Recent-updates
Adverse-event-management
Myeloma-cancer
Relapsed-refractory-multiple-myeloma
Multiply-relapsed
Later-line-treatment
Later-line-therapy
Adverse-events
Drug-adverse-event
Diffuse Large B-Cell Lymphoma: Moving Novel Therapy to the Frontline Setting
Expert perspectives on recent efforts to move novel therapy from the relapsed/refractory to frontline setting of diffuse large B-cell lymphoma.
Translating-recent-evidence
Real-world-management
Refractory-diffuse-largeb-cell-lymphoma
Largeb-cell-lymphoma
Moving-novel-therapy
Diffuse-largeb-cell-lymphoma
Dlbcl
Relapsed-refractory-dlbcl
Rr-dlbcl
Tafasitamab
Lenalidomide
Patient Scenario 3: 2L Lurbinectedin Following 1L Combination IO Chemotherapy
A panel of expert oncologists present the case of a 78-year-old woman who is treated with lurbinectedin following disease progress on first-line carboplatin, etoposide, and atezolizumab.
Evolving-treatment-strategies
Small-cell-lung-cancer
Lurbinectedin-following
Nsclc
Es-sclc
Extensive-stage-small-cell-lung-cancer
Lurbinectedin
Second-line
Disease-progression
Asco-2023
Asco-annual-meeting
Bispecifics in Multiple Myeloma: Dosing and Transition of Care
A brief review of logistical considerations that play a part in selecting novel therapy for patients with multiply relapsed multiple myeloma.
Evolving-treatment-paradigm
Multiple-myeloma
Recent-updates
Myeloma-cancer
Relapsed-refractory-multiple-myeloma
Multiply-relapsed
Later-line-treatment
Later-line-therapy
Fixed-duration-therapy
Duration-of-therapy
Duration-of-treatment
vimarsana © 2020. All Rights Reserved.